₹6,033.00
+0.02%NSE close, 16 Nov 2026
−33.54%
AstraZeneca Pharma India is a small cap company, listed on NSE under the symbol ASTRAZEN. At ₹6,033.00 a share, the market values the whole company at ₹15,083 crore.
In FY26, it reported sales of ₹2,276 crore and a net profit of ₹188 crore, an operating margin of 11.5%. Over the last three years, sales grew 31.4% a year and net profit grew 23.6% a year.
The market values the company at 84.9 times its profit over the last twelve months and 17.16 times its book value; its return on equity is 20.2% and it has almost no borrowings.
Promoters hold 75.00% of the shares. Foreign institutions hold 2.64%, and domestic institutions, mutual funds among them, 7.09%.
Over the past year the share price has fallen 34.3%, and it is 36.3% below its 52-week high.
₹ crore. Standalone figures: the company files no consolidated results.
Appointment/ Change in designation of Senior Management Personnel
| Dec 2025 |
|---|
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 306 | 383 | 388 | 408 | 440 | 480 | 526 | 559 | 612 | 579 | 683 | 729 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 | 567 | 518 | 634 | 634 |
| Operating profit | 15.1 | 49.4 | 38.1 | 52.5 | 77.0 | 86.4 | 81.1 | 75.2 | 44.8 | 60.9 | 48.9 | 95.6 |
| Operating margin | 4.9% | 12.9% | 9.8% | 12.9% | 17.5% | 18.0% | 15.4% | 13.4% | 7.3% | 10.5% | 7.2% | 13.1% |
| Other income | 9.7 | 8.7 | 8.4 | 8.2 | 8.0 | 16.2 | 11.2 | 6.2 | 5.1 | 6.0 | 9.2 | 15.1 |
| Interest | 0.6 | −0.1 | 0.1 | 0.3 | 0.3 | 0.7 | 0.7 | 0.7 | 1.1 | 2.0 | 2.0 | 1.9 |
| Depreciation | 3.7 | 3.8 | 3.9 | 9.3 | 9.1 | 17.7 | 16.6 | 2.6 | 3.8 | 5.6 | 5.2 | 5.4 |
| Profit before tax | 20.4 | 54.4 | −15.2 | 51.0 | 42.0 | 78.5 | 74.7 | 72.8 | 46.5 | 58.1 | 50.8 | 88.5 |
| Tax | 4.6 | 14.9 | −3.4 | 12.6 | 11.2 | 20.2 | 18.9 | 18.6 | 14.0 | 13.3 | 12.8 | 26.2 |
| Net profit | 15.8 | 39.5 | −11.8 | 38.4 | 30.9 | 58.3 | 55.8 | 54.2 | 32.6 | 44.9 | 37.9 | 62.3 |
| EPS (₹) | 6.32 | 15.79 | -4.72 | 15.37 | 12.34 | 23.30 | 22.33 | 21.69 | 13.04 | 17.95 | 15.17 | 24.93 |
₹ crore, financial years to March.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,716 | 2,276 |
| Expenses | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,462 | 2,014 |
| Operating profit | 71.3 | 121 | 135 | 86.2 | 165 | 184 | 254 | 262 |
| Operating margin | 9.8% | 14.5% | 16.7% | 10.7% | 16.5% | 14.2% | 14.8% | 11.5% |
| Other income | 16.3 | 13.0 | 12.8 | 14.8 | 26.1 | 34.8 | 40.6 | 28.5 |
| Interest | 0 | 1.1 | 1.1 | 1.0 | 0.6 | 1.2 | 1.5 | 4.5 |
| Depreciation | 14.9 | 18.6 | 20.1 | 17.0 | 16.3 | 14.9 | 40.0 | 28.6 |
| Profit before tax | 72.7 | 114 | 127 | 83.0 | 134 | 220 | 156 | 252 |
| Tax | 18.2 | 41.8 | 33.8 | 21.4 | 34.8 | 58.0 | 40.6 | 64.7 |
| Net profit | 54.4 | 72.2 | 93.3 | 61.6 | 99.3 | 162 | 116 | 188 |
| EPS (₹) | 21.78 | 28.88 | 37.32 | 24.64 | 39.72 | 64.60 | 46.30 | 75.01 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 101 | 65.4 | −15.1 | 232 |
| From investing | 4.7 | 30.8 | 18.7 | −5.5 |
| From financing | −9.5 | −65.6 | −92.0 | −101 |
| Spent on fixed assets | −9.6 | −1.8 | −3.6 | −15.6 |
| Free cash flow | 91.2 | 63.6 | −18.8 | 217 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | 7.5% | 8.7% | 11.5% | 7.6% | 9.9% | 12.5% | 6.7% | 8.2% |
| Operating margin | 9.8% | 14.5% | 16.7% | 10.7% | 16.5% | 14.2% | 14.8% | 11.5% |
| Return on equity | – | – | – | – | 16.9% | 22.7% | 15.0% | 21.5% |
| Return on capital employed | – | – | – | – | 22.9% | 31.0% | 20.5% | 29.4% |
| Return on assets | – | – | – | – | 10.1% | 15.0% | 7.6% | 9.4% |
| Debt to equity | – | – | – | – | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest coverage | – | 101.00 | 117.60 | 88.40 | 210.50 | 185.50 | 108.10 | 57.20 |
| Debt to assets | – | – | – | – | 0.00 | 0.00 | 0.00 | 0.00 |
| Current ratio | – | – | – | – | 2.31 | 2.61 | 1.91 | 1.76 |
| Quick ratio | – | – | – | – | 1.81 | 1.97 | 1.13 | 0.72 |
| Cash ratio | – | – | – | – | 1.30 | 1.42 | 0.76 | 0.46 |
| Asset turnover | – | – | – | – | 1.02 | 1.20 | 1.13 | 1.14 |
| Fixed asset turnover | – | – | – | – | 14.57 | 21.46 | 26.99 | 19.37 |
| Inventory turnover | – | – | – | – | – | 2.60 | 1.80 | 1.30 |
| Receivables turnover | – | – | – | – | 9.30 | 8.50 | 9.30 | 10.60 |
| Gross margin | – | – | – | – | – | 54.1% | 43.9% | 39.3% |
| Cash from operations to profit | – | – | – | 164.0% | – | – | 56.0% | -8.0% |
| Effective tax rate | 25.1% | 36.6% | 26.6% | 25.8% | 26.0% | 26.4% | 26.0% | 25.6% |
Appointment of Chief Financial Officer
The financial results for the period ended September 30, 2026.
AstraZeneca Pharma India announces new Mumbai corporate office, marking the next phase of growth through innovation
A copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.